Report Code: A13612 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Ustekinumab is indicated for the management of moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults and children 6 years or older who are candidates for phototherapy or systemic therapy. It is in a class of medications called monoclonal antibodies. Ustekinumab is used alone or in combination with methotrexate (rasuvo, otrexup, trexall) to treat psoriatic arthritis in adults. Psoriatic arthritis is a condition that causes joint pain and swelling and scales on the skin. Moreover, it is also used to treat Crohn's disease and ulcerative colitis. However, Crohn's disease is a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever. Ustekinumab works by stopping the action of certain cells in the body that cause the symptoms of psoriatic arthritis, plaque psoriasis, ulcerative colitis, and Crohn's disease. Common side effects include nausea, headache, tiredness runny, stuffed nose, or sneezing, and joint pain. Furthermore, other serious side effects include seizures, vision changes, difficulty in breathing, and others.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the ustekinumab market.
Top Impacting Factors
Market Trends
New Product Launches to Flourish the Market
In February 2019, Janssen Biotech Inc., a biotechnology company, received the United States Food and Drug Administration approved TREMFYA for the treatment of severe plaque psoriasis.
In July 2020, Fujifilm Kyowa Kirin Biologics received the Japanese regulatory approval for manufacturing and marketing of the first adalimumab biosimilar in the island country for the indication of psoriasis vulgaris, arthritic psoriasis, pustular psoriasis, ankylosing spondylitis, entero-behcet's disease, and Crohn's disease.
In August 2020, Lupin Limited and Mylan launched the biosimilar etanercept Nepexto after receiving marketing authorization from the European Commission in May 2020 for indications, including psoriatic arthritis and plaque psoriasis.
Key Benefits of the Report
Questions Answered in the Ustekinumab Market Report
Ustekinumab Market Report Highlights
Aspects | Details |
---|---|
By Dosage Form |
|
By Distribution Channel |
|
By Region |
|
Key Market Players | EPIRUS BioPharma, Fuji Pharma, Alvotech, Formycon, Stada, NeuClone, Outlook Therapeutics, Meiji, Johnson and Johnson, Mitsubishi Tanabe |
Loading Table Of Content...
Start reading.
This Report and over 71,229+ more Reports, Available with Avenue Library. T&C*.
10%
Discount
10%
Discount
15%
Discount
15%
Discount
Enterprise
License/PDF
20%
Discount
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers